XM does not provide services to residents of the United States of America.

British Business - August 8



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>PRESS DIGEST-British Business - August 8</title></head><body>

Aug 8 (Reuters) -The following are the top stories on the business pages of British newspapers. Reuters has not verified these stories and does not vouch for their accuracy.


The Times

- Asset manager H2O has agreed to pay out 250 million euros ($273.35 million) to investors who have been trapped since 2020 in illiquid funds linked to Lars Windhorst, the German financier.

- British inter-dealer broker TP ICAP TCAPI.L said it was considering a U.S. listing for its data and analytics business, sending shares to a more than three-year high.


The Guardian

- Thousands of police and anti-racism protesters gathered on streets across Britain on Wednesday to challenge expected far-right groups that failed to materialise following more than a week of violent racist attacks targeting Muslims and migrants.

- Glencore GLEN.L will keep its coal business after securing backing from a majority of its investors who see lucrative earnings from the fossil fuel, its CEO said on Wednesday, adding the company could acquire more steelmaking coal assets.


The Telegraph

- Fast fashion retailer Boohoo BOOH.L is seeking to offload its office in London's Soho as it battles to shore up its balance sheet.

- GB News has said it is "closely monitoring" Elon Musk's lawsuit against advertisers in a sign it is preparing to sue brands that suspend advertising.


Sky News

- British Land BLND.L is considering voting against a restructuring of Cineworld's CINE.D British operations that could lead to the closure of dozens of sites.

- Britain's National Health Service (NHS) will begin to roll out a gene therapy from Vertex Pharmaceuticals VRTX.O and CRISPR Therapeutics CRSP.BN to treat rare blood disorder beta thalassemia.


($1 = 0.9146 euros)




(Compiled by Bengaluru newsroom)

</body></html>

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.